🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsHas anyone dealt with glp-1r expression map?

Has anyone dealt with glp-1r expression map?

mike_mod Fri, Oct 18, 2024 at 7:09 PM 35 replies 1,913 viewsPage 1 of 7
This thread is more than 19 months old. Information may be outdated. Consider searching for more recent discussions.
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Oct 18, 2024 at 7:09 PM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.

What I actually want to know is which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working. Practical detail welcome, however dull — the duller the better.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
2 22PharmHunterJen, TomTeleRx
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Oct 18, 2024 at 7:16 PM#2
mike_mod said:
The mechanism is more central than most summaries suggest.

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest trajectory ever seen for an anti-obesity agent[1].

Amylin receptor agonism enhances satiety signaling through the area postrema and reduces glucagon secretion. Combined with GLP-1R agonism, this dual mechanism may produce even greater efficacy than current agents.

Early-stage data — interpret with caution. But the trajectory is extraordinary.

References:
[1] Novo Nordisk investor presentation, September 2023.
1 21NauseaFreeNow
Reply Quote Save Share Report
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Oct 18, 2024 at 7:23 PM#3
mike_mod said:
The mechanism is more central than most summaries suggest.

I read this differently from mike_mod, on substance rather than tone. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

50 20oliver_london, tane_welly, Dr.PathRoch and 47 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Oct 18, 2024 at 7:30 PM#4
Dr.PainCLE said:
The pharmacokinetics explain nearly every practical question asked here.

Pharmacist here. I want to add the drug interaction perspective on the pharmacology.

Key points from a pharmacokinetic standpoint:

  • GLP-1 agonists delay gastric emptying, which can affect Tmax of co-administered oral medications
  • Monitor patients on warfarin (INR), levothyroxine (TSH), and oral contraceptives during dose titration
  • The albumin-binding mechanism of semaglutide (C-18 fatty acid linker) gives it the ~168-hour half-life that enables weekly dosing
  • Steady state is reached at approximately 4-5 weeks after dose initiation or adjustment

Re: the pharmacology specifically — the pharmacology here is well-characterized and the clinical implications are straightforward.

49 19PeptideChemSF, A1cHero_PHX, Dr.RenalNash and 46 others
Reply Quote Save Share Report
james_edin
Member
289
1,234
Sep 2024
Edinburgh, UK
Oct 18, 2024 at 8:07 PM#5
Dr.NateNeph said:
Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

Same experience, arrived at from the opposite direction. The detail I would add is minor and it is already implied above.

Last edited: Oct 18, 2024 at 10:07 PM
48 18bbq_ray_KC, oliver_london, tane_welly and 45 others
Reply Quote Save Share Report
1237

Similar Threads

GLP-1R desensitization — β-arrestin-mediated internalization18 replies
Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register